10/3/2018 | CVLM | Immunomedics offers stock in swap for $12.9 million convertibles
|
9/15/2017 | CVLM | Immunomedics offers stock in swap for $80 million 4.75% convertibles
|
2/10/2017 | CV | Market Commentary: Microchip’s new deals trade ‘around par’ post-pricing; Acorda gains; Immunomedics rises
|
1/19/2017 | CV | Market Commentary: Market awaits new deals from Hercules, Liberty; Nabors in focus; Finisar convertibles firm
|
10/17/2016 | CV | Market Commentary: Health care convertibles in focus, weaker; Take-Two jumps outright on game chatter
|
6/6/2016 | CV | Market Commentary: Planned Medicines’ $350 million deal looks ‘fair’; Weatherford expands; Nevro on tap
|
6/3/2016 | CV | Market Commentary: Weatherford extends gains after strong debut; Alibaba mandatory trades a little below par
|
10/19/2015 | PP | Market Commentary: PTC Therapeutics drops; Immunomedics adds about 3 points; Campus Crest trades around par
|
10/19/2015 | CV | Market Commentary: PTC Therapeutics drops; Immunomedics adds about 3 points; Campus Crest trades around par
|
2/12/2015 | CV | Immunomedics greenshoe exercise raises convertibles to $100 million
|
2/6/2015 | PP | Market Commentary: New, upsized Microchip trades actively around issue; old Microchip flat; LinkedIn comes in
|
2/6/2015 | CV | Market Commentary: New, upsized Microchip trades actively around issue; old Microchip flat; LinkedIn comes in
|
2/5/2015 | CV | New Issue: Immunomedics prices $85 million 4.75% five-year convertibles, up 27.5%
|
2/5/2015 | PP | Market Commentary: New Microchip flat to higher in gray market, old bonds active; Twitter adds ahead of earnings
|
2/5/2015 | CV | Market Commentary: New Microchip flat to higher in gray market, old bonds active; Twitter adds ahead of earnings
|
2/5/2015 | CV | Market Commentary: Morning Commentary: New Microchip looks cheap ahead of final terms; old Microchip trading actively
|
2/4/2015 | CV | Immunomedics to price $85 million five-year convertibles to yield 4.25%-4.75%, up 25%-30%
|
5/2/2014 | PP | Immunomedics prices $30.15 million public offering of stock at $3.35
|
5/1/2014 | PP | Immunomedics announces plans to price public offering of common stock
|
2/27/2013 | PP | Immunomedics greenshoe exercised for $16.1 million public stock sale
|
2/22/2013 | PP | Immunomedics prices $14 million public sale of common stock at $2.30
|
2/21/2013 | PP | Immunomedics reports plans to price public offering of common stock
|
5/2/2007 | PP | Market Commentary: Immunomedics secures $24 million from direct stock deal; Neurochem plans $80 million convertible sale
|
5/2/2007 | PP | New Issue: Immunomedics secures $24 million from direct placement of stock
|
11/6/2006 | BT | Immunomedics reports Q1 revenues of $3.3 million, net loss of $2.5 million
|
9/26/2006 | BT | Immunomedics, UCB suspend epratuzumab trials due to manufacturing concerns
|
8/29/2006 | BT | Market Commentary: Teva lower; Endo, Penwest up; StemCells gains 7%; Nastech higher; Hemispherx rises 11%
|
8/25/2006 | BT | Immunomedics: fourth-quarter revenues up to $2.2 million thanks to UCB licensing payment
|
6/5/2006 | BT | Immunomedics constructs new bispecific antibodies
|
6/2/2006 | BT | Immunomedics' 131I-Labetuzumab found safe in colorectal cancer patients
|
5/10/2006 | BT | Immunomedics licenses developing, marketing rights for epratuzumab to UCB
|
4/25/2006 | BT | Immunomedics, IBC Pharmaceuticals report on new platform technology
|
4/24/2006 | BT | Immunomedics study shows epratuzumab improved Bilag scores in 92% of lupus patients studied
|
12/16/2005 | BT | Immunomedics' pancreatic cancer blood test looks promising in phase 1 trial
|
12/15/2005 | BT | Immunomedics' CD74-RNase shows activity against lymphoma, myeloma in preclinical studies
|
12/12/2005 | BT | Immunomedics reports Anti-CD20 safe, active for non-Hodgkin's lymphoma
|
12/9/2005 | BT | Immunomedics' epratuzumab-rituximab combo shows efficacy in lymphoma study
|
11/15/2005 | BT | Immunomedics says phase 1/2 trial of epratuzumab shows promise for Sjogren's syndrome
|
9/13/2005 | BT | Market Commentary: Immunomedics up; OSI rebounds; Celgene retreats; Protein Design Labs, Novavax, Cephalon all up
|
9/12/2005 | BTPP | Immunomedics looking for more financing to fund research in coming 12 months
|
9/6/2005 | BTPP | Immunomedics to keep trading on Nasdaq after positive ruling from appeal panel
|
7/20/2005 | BTPP | Immunomedics amends exchange offer for 5% convertible notes
|
7/5/2005 | BTPP | Immunomedics starts exchange for convertibles, warrants
|
5/3/2005 | PP | Market Commentary: Sequoia Oil deal leads private placements; modest stock gains, lower oil stall volume
|
5/2/2005 | PP | New Issue: Immunomedics closes upsized private placement of notes for $37.67 million
|
5/2/2005 | PP | Market Commentary: Immunomedics raises $37.7 million from notes offering; oil, stocks push volume
|
4/27/2005 | PP | New Issue: Immunomedics raises $36 million in private placement of notes
|
4/27/2005 | PP | Market Commentary: Enterra Energy gets C$100 million equity line; stocks boost volume slightly
|
4/23/2004 | CV | Immunomedics registers $10 million 3.25% convertibles
|